patent cliffs, stagnant pipelines, the end of the blockbuster era, etc. In reality, the prospects of the biopharmaceutical sector — for patients in search of new medicines, for policy makers seeking value in the health care system and for
If initial indications offer any guarantee of an eventual outcome, Mike Bloom’s arrival as president and chief operating officer at Family Dollar Stores promises to benefit the dollar retailer in ways almost too numerous to detail.
With the end of the year less than three weeks away, it appears all but certain that Walgreens will not be part of Express Scripts’ network of pharmacy providers when 2012 gets under way.
This has been a stunning year for chain drug retailing, a period punctuated by dramatic changes in both direction and personnel.
Retail pharmacy operators continue to find themselves on the firing line as government officials work to rein in health care spending and address worrisome long-term budget deficits. Medicaid, the federal/state program that provides health care for the indigent, is a case in point.
Change never comes easily, especially for a company blessed with success. Why change, the thinking goes, when what we’re doing apparently works so well? That’s been Walgreens’ dilemma. Very few retailers, and no drug chains, have enjoyed the success Walgreens has found over the past 30 years.
It’s time for people in the chain drug industry to take another look at Rite Aid, whose long, painful turnaround has started to gain traction in recent months. For more than a decade the company has been widely viewed as something of an invalid, a status that resulted from self-inflicted wounds.
The people who founded, built and served the chain drug industry in this country during its halcyon days are rapidly disappearing from the scene. During the summer death claimed Charlie Bowlus, the founder and driving force behind ECRM.
Many drug chains can take justifiable pride in their efforts to rethink the shopping experience. Walgreen Co., Rite Aid Corp.
When Len DeMino retired earlier this month after over 50 years of service to the profession of community pharmacy, he closed the door on the golden era of chain drug retailing, an era he helped define.
Whatever one thinks of the health care reform legislation, whose most far-reaching provisions are due to take effect in 2014, it should be welcome news that the Obama administration has asked the Supreme Court to consider the ongoing legal challenges to the law.
or even distant — memory has a mass retailer tapped an outsider to head up its executive ranks. Yet that’s what is about to happen, on October 1, when Mark Cosby officially becomes president of the CVS/pharmacy unit of CVS Caremark. It is a daunting assignment. Depending on how one calculates
When Andy Giancamilli steps down as chief executive officer of Katz Group Canada at the beginning of February, his move to an advisory role at the company will mark the end of a career in community pharmacy that exemplifies what the profession means for the people who practice it and the patients it
The final goodbyes have been said, the last stories told. Only the memories of Charlie Bowlus linger, the memories of the personality behind the organization that charted new directions, opened new windows, explored new possibilities and developed new ways of doing business.
The talk surrounding Hurricane Irene’s impact on the National Association of Chain Drug Stores Pharmacy and Technology Conference obscures what’s important.
